Impact of Telaprevir-Based Treatment Regimens on Fatigue in Genotype 1 HCV Treatment-NaiVE Patients: Results From Advance and Illuminate Studies

被引：0
|
作者：
Muir, Andrew J.
Gavan, Sandra
Thal, Gary
Nuyts, Guy
McCallister, Scott
Beumont-Mauviel, Maria
Luo, Don
Adda, Nathalie
Wright, Christopher I.
Sherman, Kenneth E.
机构：
来源：
GASTROENTEROLOGY | 2011年 / 140卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S944 / S945
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of telaprevir-based treatment for elderly patients with genotype 1 chronic hepatitis C
    Furusyo, N.
    Murata, M.
    Ogawa, E.
    Nomura, H.
    Hayashi, J.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2013, 42 : S130 - S130
  • [32] THE COMPARATIVE EFFICACY OF TELAPREVIR VERSUS BOCEPREVIR IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS
    Diels, J.
    Cure, S.
    Gavart, S.
    VALUE IN HEALTH, 2011, 14 (07) : A266 - A266
  • [33] Telaprevir Activity in Treatment-Naive Patients Infected With Hepatitis C Virus Genotype 4
    Sefcik, Roberta K.
    Bichoupan, Kian
    Martel-Laferriere, Valerie
    Odin, Joseph A.
    Liu, Lawrence U.
    Perumalswami, Ponni
    Bansal, Meena
    Dieterich, Douglas T.
    Ahmad, Jawad
    Schiano, Thomas D.
    Branch, Andrea D.
    JOURNAL OF INFECTIOUS DISEASES, 2014, 210 (11): : 1855 - 1856
  • [34] INTERIM SVR12 RESULTS FROM THE TELAPREVIR PHASE 3B REPLACE STUDY IN TREATMENT-NAIVE STABLE LIVER TRANSPLANT PATIENTS WITH GENOTYPE 1 HCV INFECTION
    Forns, X.
    Samuel, D.
    Mutimer, D.
    Fagiouli, S.
    Navasa, M.
    Agarwal, K.
    Berenguer, M.
    Colombo, M.
    Herzer, K.
    Nevens, F.
    Van Solingen-Ristea, R.
    Luo, D.
    Dierynck, I.
    Witek, J.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S481 - S481
  • [35] COST-EFFECTIVENESS OF TRIPLE THERAPY WITH TELAPREVIR FOR THE TREATMENT OF TREATMENT-NAIVE GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS IN GERMANY
    Stahmeyer, J. T.
    Schauer, S.
    Wirth, D.
    Fleischmann, J.
    Lee, S.
    Gavart, S.
    Bianic, F.
    Cure, S.
    Krauth, C.
    VALUE IN HEALTH, 2012, 15 (07) : A396 - A396
  • [36] Work productivity among treatment-naive patients with genotype 1 chronic hepatitis C infection receiving telaprevir combination treatment
    Aggarwal, J.
    Vera-Llonch, M.
    Donepudi, M.
    Suthoff, E.
    Younossi, Z.
    Goss, T. F.
    JOURNAL OF VIRAL HEPATITIS, 2015, 22 (01) : 8 - 17
  • [37] Telaprevir combination therapy in treatment-naive and experienced patients co-infected with HCV and HIV
    Montes, Marisa
    Nelson, Mark
    Girard, Marie
    Sasadeusz, Joe
    Horban, Andrzej
    Grinsztejn, Beatriz
    Zakharova, Natalia
    Falconer, Karolin
    Dierynck, Inge
    Luo, Donghan
    Ma, Yi-Wen
    Witek, James
    HEPATOLOGY, 2013, 58 : 225A - 226A
  • [38] Optimal IFN-free therapy in treatment-naive patients with HCV genotype 1 infection
    Asselah, Tarik
    Marcellin, Patrick
    LIVER INTERNATIONAL, 2015, 35 : 56 - 64
  • [39] TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA2A AND RIBAVIRIN FOR 24 OR 48 WEEKS IN TREATMENT-NAiVE GENOTYPE 1 HCV PATIENTS WHO ACHIEVED AN EXTENDED RAPID VIRAL RESPONSE: FINAL RESULTS OF PHASE 3 ILLUMINATE STUDY
    Sherman, Kenneth E.
    Flamm, Steven L.
    Afdhal, Nezam H.
    Nelson, David R.
    Sulkowski, Mark S.
    Everson, Gregory T.
    Fried, Michael W.
    Kleber, Kristin
    Martins, Marie
    Sankoh, Abdul J.
    Kauffman, Robert S.
    George, Shelley
    Wright, Christopher I.
    Poordad, Fred
    HEPATOLOGY, 2010, 52 (04) : 401A - 402A
  • [40] Predictors of Days Unable to Work Among Genotype 1 Treatment-NaiVE Chronic Hepatitis C Patients: Post-Hoc Analyses of Data From Phase 3 Advance and Illuminate Studies
    Hernandez, Ning C.
    Vera-Llonch, Montserrat
    Aggarwal, Jyoti
    Donepudi, Mrudula
    Younossi, Zobair M.
    Goss, Thomas F.
    GASTROENTEROLOGY, 2012, 142 (05) : S955 - S955
12345